Home / Transcripts / Myomo, Inc. (MYO) · November 10, 2025

Myomo, Inc. (MYO) Earnings Call Transcript

November 10, 2025

NYSE American US Health Care Health Care Equipment and Supplies earnings 41 min

Earnings Call Speaker Segments

Tirth Patel executive
#1

Thanks, Operator, and good afternoon to all of you. I'm Tirth Patel, calling in from Alliance Advisors IR. I'd like to welcome everyone to the conference call covering Myomo's financial results for the third quarter of 2025. Joining me today are Paul Gudonis, Myomo's Chief Executive Officer, and Dave Henry, the company's Chief Financial Officer. Before we get started, I want to remind listeners that anything management says on this call that isn't a historical fact counts as a forward-looking statement. Terms such as anticipate, believe, estimate, expect, intend, guidance, outlook, confidence, target, project, along with similar expressions, are generally the way such forward-looking statements get flagged. These forward-looking statements don't amount to guarantees regarding future performance, and they may involve and are subject to risks, uncertainties, and other factors that could impact Myomo's business, financial condition, and operating results; those risks, uncertainties, and other factors get covered in Myomo's filings with the Securities and Exchange Commission. What actually happens and what results we actually deliver could differ materially from anything expressed in or implied by these forward-looking statements. On top of that, unless the law demands it, Myomo takes on no obligation to revise or update any forward-looking statements so they reflect events or circumstances arising after today's call date, November 10th, 2025; at this point I'm happy to hand things over to Myomo's CEO, Paul Gudonis. Paul, the floor is yours.

Paul Gudonis executive
#2

Thank you, Tirth. Good afternoon, everyone, and we appreciate you being with us today. I'm happy to report that Myomo delivered another robust quarter, with revenue reaching $10.1 million, which landed at the upper end of what we had expected. The drivers behind this were record-setting revenues across our international markets along with a rising count of O&P providers. Beyond that, our pipeline grew, and for the first time this year, both quarterly authorizations and orders rose on a sequential basis. We're observing a greater number of Medicare Advantage payer authorizations and orders stemming from the new in-network contracts that we signed earlier this year. Before Dave takes over to go through the financials in detail, I'd like to talk about how we did this quarter on the main initiatives we outlined last call. Those were: first, getting better at finding and qualifying potential patients; second, growing the Myo Connect program along with the O&P channel; third, broadening insurance coverage; and fourth, bringing down our total operating costs. To start, as I noted earlier, the central focus for us has been improving the way we find and qualify potential patients. We're seeing a steady increase in the number of new patient candidates who meet the criteria for MyoPro, and because we changed how our advertising media is mixed, the cost for each pipeline addition has begun to come down. In Q3, we shifted a greater portion of our advertising budget toward TV and away from social media, which yielded a larger share of leads that met our clinical requirements to become a successful patient, and these candidates also tend to be more motivated to complete the screening process quickly. Because of this, the standard of our pipeline ads went up, and at the same time we saw the count of candidates in the pipeline rise from one period to the next. A new head of marketing has joined us, someone with deep background in healthcare, direct-to-consumer advertising, and B2B marketing, and this person is here to back our efforts, especially when it comes to strengthening what we tell physicians, therapists, and O&P practitioners. Across our different media, we will make the most of every channel to teach patients, family members, clinicians, and payers about what MyoPro can do for them. Next, in our view, the way to bring customer acquisition costs down is to build repeatable streams of patients that are not tied to whether a potential candidate decides on their own to respond to a paid advertisement. This matters a great deal for our new MyoConnect initiative and for the expanding O&P business. Early results from our MyoConnect clinical referral effort look promising — therapists and physicians at rehabilitation clinics nationwide are sending us patients of high quality. A key point: we spend nothing on advertising to teach these clinicians and patients, because relationships with them already exist. Halfway through the year we rolled out MyoConnect, with our field clinical staff connecting in person with therapists and physicians throughout the country, widening the group of clinicians who grasp what MyoPro can do for people. These practitioners, the ones who shape and carry out each patient's treatment plan, are able to send suitable patients our way and to our O&P partners in local markets. For a number of years now, we've been educating a great many occupational therapists, and they have witnessed how much better patients function thanks to the MyoPro. What made them willing to send patients our way was CMS deciding to reimburse the MyoPro under Medicare, along with the launch of the new MyoPro 2x model last spring. As a result, we're starting to see a growing number of OTs and physicians directing their patients to us so they can get a MyoPro. It's still early in this rollout, but the initial traction has us encouraged, and we think that over time this program can become a scalable, cost-efficient source of high-quality referrals. The O&P channel is another place where we see recurring orders, and we keep delivering clinical and reimbursement education and certification to O&P practitioners — that's the mechanism for expanding adoption in this channel. In September, we were at the American Orthotics and Prosthetics Association National Assembly, the biggest trade show serving the O&P industry. Our meetings with both existing and prospective channel partners were productive, and I'm confident that sales to these clinics will keep growing as we diversify our revenue sources beyond direct-to-consumer advertising and direct billing. On the earnings call, the company reported that its new O&P channel generated more than twice the revenue it had a year before, and the patient pipelines tied to that channel keep growing, which the company credits to the training and clinical support it provides to certified prosthetist orthotists. Over a recent 45-day stretch, the speaker held meetings with senior managers from both large and small O&P clinical groups across the industry, working together to make the MyoPro available to their patients. The company has strong working relationships with these organizations, and according to the speaker, they are keen to team up with MyoPro on initiatives aimed at easing upper extremity impairments for a key portion of the patients they serve. As the speaker noted, these groups already use a range of lower extremity assistive devices to help stroke patients get around. Meanwhile, our O&P distribution partners based in Germany submitted an all-time-high volume of orders during the quarter. That fueled significant revenue gains in our business outside the U.S. and added more patients to the pipeline for ongoing expansion. As for broadening insurance coverage, our Chief Medical Officer and the reimbursement group have been in ongoing discussions with the leading Medicare Advantage insurers, seeking additional MyoPro authorizations on behalf of their members. For patients enrolled in certain of those plans, and for payers we hold contracts with, we recorded a quarter-over-quarter rise in authorizations. Those encouraging outcomes contributed to the larger tally of authorizations and orders in the quarter just ended. In the third quarter, we added another agreement with a payer, making us an in-network option for our direct billing operations. That takes us up to 35 million covered lives across private payers. Additional contracts are in the works, and these will also help more patients on commercial health insurance plans get access to MyoPro. On top of that, something is happening in the payer sector that might benefit Myomo. A number of insurers offering Medicare Advantage plans are withdrawing that coverage from certain areas, which reduces their membership counts. UnitedHealthcare, for example, anticipates shedding 1 million members, and other payers are making similar announcements. Should such patients decide to sign up for traditional fee-for-service Medicare, those whose medical condition makes them eligible for MyoPro could stand a better chance of receiving our device for their paralyzed arms via Medicare Part B coverage. Backed by better reimbursement, we kept expanding the published body of research regarding MyoPro throughout Q3. A systematic review covering patient outcomes tied to use of the myoelectric orthosis appeared in the well-regarded Topics in Stroke Rehabilitation journal. Sharing such data with payers, rehab physicians, and therapists, along with O&P professionals, may yield broader insurance coverage and clinical adoption. Finally, in the quarter we rolled out manufacturing adjustments aimed at raising our gross margin, and we also controlled headcount plus other cost cuts in order to bring operating expenses down; this positions us for stronger operating leverage as future revenues grow, driven by a bigger patient pipeline strengthened by the greater count of authorizations and orders we anticipate from the Myo Connect program and the broader O&P channel. With the Q4 backlog we're starting from and the volume of patient cases working their way through reimbursement, we're able to restate our guidance for the full year 2025 at $40 million-$42 million, which represents growth of more than 23% over the prior year; now that I've walked through those results and the actions we've taken, I'll turn things over to Dave Henry, our CFO, who will go deeper into the financials and the details of the term loan facility we recently closed, which is intended to provide growth capital so we can continue scaling the business toward sustainable profitability and positive cash flow as MyoPro volumes and revenue increase.

Dave Henry executive
#3

Thanks, Paul, and good afternoon to all of you. I'd like to begin by going over how we performed financially in the third quarter. Our revenue came in at $10.1 million for Q3 2025. That's up 10% compared with the same period a year earlier, and the growth came from shipping more revenue units, partly offset by a decline in average selling price, or ASP. During the quarter, we delivered 186 MyoPro revenue units, which is a 16% rise, and 57% of those units came from authorizations and orders booked within the third quarter. Versus the prior year, our ASP fell 5% to roughly $54,300, and sequentially it was about flat. The prior-year ASP was abnormally elevated because of the shift in revenue recognition for Medicare patients to the point of delivery rather than at the time of payment. During that period, we started recognizing Medicare and certain supplemental revenues upon delivery, alongside some recognized at payment for deliveries made before the accounting change. That accounting change gave ASP a favorable boost of about $4,300 in the third quarter of 2024. If you normalize for that accounting change, ASP rose 3% year-over-year. In the third quarter, Medicare Part B patients accounted for 54% of revenue. Medicare Advantage made up 18% of third quarter revenue, and measured in dollars, it declined 18% from the prior year. Medicare Advantage revenue is still held back by the large volume of pre-authorization denials, which pushes us into an appeals process so we can serve these patients; Myomo isn't alone in facing this. Sadly, a lot of insurance companies steer patients into that process, betting they won't appeal. Success rates on appeals differ, but for those who remain engaged with us while trying to obtain a MyoPro, we generally see somewhere around 45%-50% get overturned on appeal; we keep working with these payers so that deserving patients can access the technology they need for a fuller, more productive life after injury. The direct billing channel generated 73% of third quarter revenue, versus 81% in the same quarter last year. International revenue hit a record $1.8 million for the quarter, up 63% and equal to 18% of total revenue, mostly from Germany. Revenue in the O&P channel also set a quarterly record at $900,000, up 154% year-over-year and accounting for 9% of total revenue. As Paul noted, the O&P channel is becoming a high-quality, lower-cost source of qualified patients, and we plan to keep growing it. As of September 30th, 2025, the pipeline totaled 1,669 patients, which is 32% higher year-over-year. In the third quarter, we added 826 patients to the pipeline, up 28% from the prior-year quarter and up 1% sequentially. The pipeline included 266 Medicare patients, a 21% increase year-over-year and 4% sequentially. We closed the quarter with a backlog of 208 patients, down 34% versus the prior year. Just to recap what backlog means: it's the insurance approvals and orders we've gotten but haven't yet turned into revenue — specifically for Medicare Part B patients whose medical records we've gathered and who we've determined meet our inclusion criteria for delivery. The drop reflects fewer Medicare Advantage authorizations, plus the reality that intra-quarter fill units now account for a growing share of what we bring in each quarter. Put another way, we converted a larger portion of backlog into revenue more quickly. In fact, intra-quarter fill units made up 57% of third-quarter revenue units, compared with 24% the year before; during the third quarter we received 229 authorizations and orders, which is 11% higher sequentially and 2% higher year-over-year. Those stronger authorizations and orders helped us produce record revenue from intra-quarter fill units. For the third quarter of 2025, gross margin came in at 63.8%, versus 75.4% in the prior year quarter. Last year's gross margin got a favorable boost from the change in accounting for Medicare patient revenues I referenced earlier, which lifted third quarter 2024 gross margin by roughly 200 basis points. On top of that, as we grew, we opened a new facility and brought on more staff, which pushed payroll and lease expense higher. Lastly, gross margin took a hit from an unfavorable shift in the overhead absorbed in inventory during the third quarter of 2025, along with greater material costs. Those higher labor and overhead costs and the absorption change dragged gross margin down by about 800 basis points, and that's an opportunity for gross margin improvement as activity picks up. Total operating expenses in the third quarter of 2025 reached $10 million, 26% above the third quarter of 2024 but 6% lower sequentially. The rise came mainly from greater payroll and advertising spending, and from higher R&D tied to development work on a mobile app for our MyConfig software, the MyoPro 3, and funding for a randomized control trial pilot at the University of Utah. As Paul mentioned, we're concentrating on acquiring customers more efficiently, which brought cost per pipeline add down sequentially. We're putting money into our MyoConnect platform and expect to gain more leverage as our patient growth continues. The operating loss for the third quarter of 2025 was $3.5 million, versus an operating loss of $1 million in the prior year quarter. Net loss for the third quarter of 2025 was $3.7 million, or $0.09 per share. That compares with a net loss of $1 million, or $0.03 per share, in the third quarter of 2024. In the third quarter of 2025, roughly 600,000 pre-funded warrants were exercised. As of September 30th, 2025, about 3.8 million pre-funded warrants from our 2023 offerings are still outstanding. Under GAAP accounting, these pre-funded warrants count as common stock equivalents and are part of our weighted average shares outstanding. Adjusted EBITDA for the third quarter of 2025 was negative $2.7 million, compared with negative $0.6 million for the third quarter of 2024. Moving on to the balance sheet and cash flow: as of September 30th, 2025, we held $12.6 million in cash, cash equivalents, and short-term investments. During the third quarter, cash burn came to $2.9 million, which breaks down as $1.8 million used in operating activities plus $1 million of capital expenditures tied to fitting out the extra manufacturing space we picked up in the third quarter, as well as capitalized software costs for a product development project of ours and demo unit builds. On November 4th, 2025, we signed a loan and security agreement with Avenue Capital that gives us a committed term loan facility of $17.5 million, and $12.5 million of that was funded when we closed. The other $5 million can be drawn at our discretion between November 2026 and May 2027, provided certain conditions are satisfied. Interest-only payments apply for the coming 18 months, and after that we'll pay down principal across 24 equal monthly installments. Proceeds were used to pay off the $4 million we had borrowed under our credit facility with Silicon Valley Bank, plus fees and expenses, leaving $7.6 million for general corporate purposes. On a pro forma basis for the funding at closing, net of the repayment to Silicon Valley Bank and fees and expenses, our cash balance as of September 30th, 2025, comes to $20.1 million. For additional detail on the term loan facility, please see our current report on Form 8-K filed today. Let me wrap up with our financial guidance. Based on the backlog we're carrying into the fourth quarter and the fill units we expect, our outlook for full year 2025 revenue remains $40 million-$42 million. We aren't giving specific 2026 guidance right now, but we do want to communicate that our focus in 2026 is on diversifying revenue streams, depending less on advertising-driven revenues and delivering growth via our Myo Connect platform and deeper penetration of our O&P channel in international markets; we intend to enhance operating leverage and reduce cash burn in 2026. With that financial overview, I'll hand the call back to Paul.

Paul Gudonis executive
#4

Appreciate that, Dave. Operator, at this point we're set to start fielding questions from our attendees. As we wait for that first question to come in, I want to note that on November 18th we'll be present in person at the Craig-Hallum Alpha Select Conference, taking place in New York City. Hopefully a few of you can make it there. Alright, Operator, go ahead whenever you're ready and let's begin with the first question.

Chase Knickerbocker analyst
#5

Good afternoon, and thanks for taking the questions. Maybe to begin with, could you help us put a number on how big your U.S. O&P business is right now? So just looking at domestic O&P, how many units went out into that channel during the third quarter, just to help us sort of get a sense of how that business is scaling?

Paul Gudonis executive
#6

It came to about $900,000, and I have to say it was approximately 30 units, though I'll get you the exact figure.

Chase Knickerbocker analyst
#7

That's useful, thanks. Regarding the new marketing lead you've brought on, could you give us a sense of which levers she pinpointed as possible ways to bring down the expense of acquiring customers? I understand the growing emphasis on Myo Connect, but within that direct billing channel specifically, were there any levers flagged early on — things like we should be doing this, or doing this more effectively, and so on?

Paul Gudonis executive
#8

Sure. As we went through interviews, Chase, we sought candidates with backgrounds across different media — social, TV, YouTube, and other platforms; at this moment we're conducting a thorough assessment of questions such as: how well is our TV advertising performing? Are we approaching social media correctly? What additional steps should we take to once again bring in more leads at a reduced cost per lead for qualified patients? That assessment is what's happening now. She came on board roughly 14 days ago.

Chase Knickerbocker analyst
#9

Got it. Maybe we can turn our attention toward the pipeline and related topics. We saw a distinct uptick in backlog drops. Could you walk us through what might be driving that, and what you saw over the quarter in terms of how the backlog progressed?

Dave Henry executive
#10

Sure. As for a lot of those backlog drops, my guess is that about 40% came from Germany, due to what I think was — I don't believe the backlog got refreshed for some trials that didn't convert, and there was some cleanup in Q3, I think. That probably accounts for part of the higher number of backlog drops. Like I said, roughly 40% of those drops related to that, and the rest was just normal activity. Separately, we're looking at somewhere in the range of $16 million to $17 million.

Chase Knickerbocker analyst
#11

Understood. Perhaps only one more from my side, Dave. Should we view OpEx this way going forward? In other words, how ought we to consider OpEx, sort of extending from where it landed in Q3? And related to that, could you discuss how your team views the timeline for getting back to positive Adjusted EBITDA, and roughly how you're running the company with that goal in view.

Dave Henry executive
#12

Yes. Regarding operating expenses, I'd say our intention is that, well, some increase in operating expenses is going to happen. To illustrate, we do plan to put more money into advertising, even though the rise won't be as large as what we saw in 2025. We'll also increase R&D spending, especially for the randomized control trial we are financing that I brought up previously. Beyond those items, we aim to keep operating expenses from growing to the greatest extent we can. Our goal is to produce and demonstrate our ability to produce operating leverage, with revenues rising more quickly than operating expenses. As for the point at which we return to positive Adjusted EBITDA, once more, we'll share a fuller update at the time we issue our 2026 guidance.

Chase Knickerbocker analyst
#13

Got it. Appreciate the questions.

Scott Henry analyst
#14

Thanks. Good afternoon. I've got a few questions about the metrics. First, whether or not it's reimbursement related, pipeline adds were up a bit from Q2 to Q3 — do you still see room for significant gains there, or does it get tougher? Eventually you hit some saturation point, or maybe things just level off before climbing again. How are you thinking about those pipeline adds, that top of the funnel?

Paul Gudonis executive
#15

Scott, when you look at how big the market opportunity is, the prevalence, and 0.25 million new cases annually in the U.S. alone, I don't believe we're anywhere close to saturation. We need to discover better, more innovative approaches to reach those patients. Through the O&P channel and the Myo Connect referral program, I anticipate a greater share of our patient pipeline adds will come via those channels. That, I expect, will fuel additional growth both this quarter and on into 2026. So many individuals are leaving rehab hospitals and stroke clinics with a paralyzed arm, and we want them to be aware of the MyoPro, because we've learned they're more medically qualified. They meet our screening criteria since their stroke is more recent. We also see that they're more motivated, given they may have lost use of that arm just a year ago rather than 25 years ago. They lack that kind of patient inertia. That's why we aim to capture more patients within the incidence population, which I believe will expand the pipeline while also enhancing its quality.

Scott Henry analyst
#16

Okay, got it. That's useful. Thanks. Now, turning to Q4 — the backlog you'll carry into it is going to be smaller than the one you carried into Q3. Usually, the quarter right before you draw down backlog tells us what to expect the following quarter. I realize your guidance is calling for growth, but could you sort of take us through the sequential growth from Q3 to Q4, and explain how you'll achieve it given a smaller backlog? Maybe other levers are at work, but I'd like to understand it better from where you sit. Thanks.

Dave Henry executive
#17

Yeah. Clearly, that's going to come from fill units as well as authorizations and orders booked during the quarter. You're right that backlog is lower, but we've also been showing that when authorizations and orders come in, our operations can actually convert them to revenue more quickly. That's where we expect that fourth-quarter growth to come from.

Scott Henry analyst
#18

All right, so it's fair to assume that trend carries on and maybe even picks up speed. I'm not sure — day trippers, so to speak, folks who arrive and leave within the same quarter.

Dave Henry executive
#19

My sense is that as authorizations and orders rise, the count of fill units we've got — speaking purely in whole numbers — will likely climb as well over time.

Scott Henry analyst
#20

All right. Excellent. So I suppose for my last question — and this one's a bit strategic in nature — there's always a somewhat elevated risk profile when you take on debt while posting losses. What I'm asking is whether this signals that you believe — I mean, clearly there are 18 months of runway before repayment has to begin. Given your confidence in your capacity to carry this debt, do you think that 18 months from now you could be nearing breakeven? I'm just trying to understand the reasoning behind choosing debt rather than equity, even though I realize you're probably not pleased with where the share price sits, but of course, debt carries a certain level of risk with it.

Paul Gudonis executive
#21

Sure. To begin with, I'd say we wouldn't have entered into this transaction unless we felt confident in our ability to repay it. That was truly the primary criterion. I think that also implies that during the 18 months before repayment obligations begin, we would anticipate not burning cash by the time we reach that point. We're running the business in that manner — through continued revenue growth, by restraining the increase in operating expenses, and by producing more incremental operating income from those added revenues. We believe we could pay it back, clearly. That was the first criterion; it represented the best combination of capital offered to us with the least amount of dilution; we've been extremely consistent that if we were going to seek additional capital, we wanted to pursue it in the least dilutive manner available; we feel we achieved that.

Scott Henry analyst
#22

All right, I appreciate the perspective on how that call got made — that's helpful. That covers everything I had. Thanks for fielding it.

Paul Gudonis executive
#23

Sure thing. Appreciate it, Scott.

Anthony Vendetti analyst
#24

Oh, hello there. This is Anthony. So, Paul and David, when it comes to the O&P clinics, what's the count on those trained up to now? Is there a target you have in mind regarding how many you want by the close of 2025 or the close of 2026? I was hoping you might go into a bit more depth about Myo Connect, what's driving that effort, and what you're aiming to achieve with it? Thanks.

Paul Gudonis executive
#25

Yeah. Hi, Anthony. So we've been putting a lot of O&P clinicians through training, though they're at differing points in getting certified. To give you an example, a couple of hundred have completed the online course covering how to assess a patient. And for those who've progressed to bringing that patient in for an evaluation, our clinical team comes out in person to conduct the evaluation alongside them. So that's extra training on top; after that, they need to fit three units before they're fully certified. So that figure keeps climbing. The good news is there's a great deal of interest from Hanger clinicians across the country. We've also got the other big players, such as Ottobock, which has a number of clinicians. Össur has its Four Motion clinics. Össur has around 90 clinics. We keep running seminars covering reimbursement, clinical training, and how to handle marketing too. Our aim is that we'll have a couple of dozen, I'd say, actively placing orders this year. Our aim is to keep growing that. I think what you'll observe is — I've brought this up on earlier calls — someone places one order, sees how it turns out for their patients, gets good outcomes, makes sure the reimbursement check arrives, and then they place another one. It begins to gain momentum from there. When it comes to Myo Connect, one asset in our corner is that we have a dozen field clinicians, mostly occupational therapists, who know the MyoPro inside and out; they're constantly in these rehab hospitals, teaching therapists how to work with users receiving a new MyoPro. Each month we train somewhere between 80 and 100 new therapists. While doing that, we give in-service presentations, and we're now seeing more and more clinical referrals. We believe that will become a genuine source, because the strategic shift I'm aiming to carry out here is moving away from one-time, somewhat advertising-driven orders from a patient toward recurring sources of patients. Those sources are O&P providers in the U.S. and Germany plus rehab hospitals, which will hopefully supply us with a steady stream of new patient candidates. That's roughly the shape of the Myo Connect program.

Scott Henry analyst
#26

All right. And finally, this might be aimed more at David, but regarding reaching breakeven, is there anything new on the quarterly revenue run rate that would be needed, or on when that might happen?

Dave Henry executive
#27

Earlier this year, when we cut headcount, before doing so, we had provided some guidance that roughly $17 million-$18 million in quarterly revenue was needed to reach breakeven. Following that July headcount reduction, I believe we saved approximately $1 million per quarter from that figure. I would put it at about $16-$17 million.

Scott Henry analyst
#28

Alright, that sounds good. Thank you. I'll jump in again with you. I appreciate that.

Paul Gudonis executive
#29

Our following question is from Sean Lee at H.C. Wainwright. Please proceed.

Sean Lee analyst
#30

Hi there. Good afternoon, everyone, and I appreciate you answering my questions. There are just a couple I want to ask quickly. To start, I believe you said revenue out of Germany came to $1.8 million during this quarter. That looks like it's growing pretty nicely. Could you share some detail about why, and what's driving that rise?

Dave Henry executive
#31

Sean, we've built up a group of more than 100 O&P channel partners in that country across the past few years. Over in Germany, things have gone really well with the statutory health insurers, which means practically anybody there who qualifies on medical grounds for the MyoPro is able to obtain one. We aren't forced to deal with the kinds of pre-authorization difficulties that occasionally come up for us in this country with certain payers, where we end up filing appeals and similar things. If a patient meets the medical criteria, they can receive a MyoPro, and that has played a part in fueling the expansion in Germany.

Sean Lee analyst
#32

Got it, thank you. For my final question, I want to ask about ad spending. Given the shift toward putting more emphasis on TV, do you feel you've now hit a new plateau with that ad spending, or should we expect it to rise further in Q4? What effect does that have on your pipeline? And what effect do you anticipate on your cost per pipeline ad?

Dave Henry executive
#33

Like I said a bit earlier, our plan is to put more money into advertising in 2026, though not growing at the same pace as we saw in 2025. Advertising spending growth will come in lower in 2026 compared with 2025. The larger effect, I believe, could come from MyoConnect along with certain initiatives in the O&P channel when it comes to expanding pipeline ads. Clearly, for the dollars we put into advertising, that yields more pipeline ads. Our aim is to raise the quality of pipeline ads, since, as Paul noted, individuals within the incident population whom the MyoConnect program specifically targets are nearer to their pre-stroke life in terms of remembering how things were prior to the stroke; our belief is that they will have greater motivation. Pipeline quality ought to get better. For a pipeline add generally, as the patient mix coming through referrals and through the O&P channel rises, conversion of those pipeline adds into revenue ought to climb over time; that's the purpose behind this; we're running Myo Connect with the staff we currently have. At present, we aren't putting extra money toward it; those are the reasons we're pursuing this and why we believe pipeline adds ought to expand. Beyond that, the quality of the add ought to improve in 2026.

Sean Lee analyst
#34

All right, that definitely clears things up considerably. I appreciate it. That's everything from me.

Dave Henry executive
#35

Very well, Sean. Thanks.

Ed Woo analyst
#36

Thanks for taking my question. It seems like Germany is still performing very well internationally. How are the other markets outside the US doing, and is there anything new regarding the partnership in China?

Paul Gudonis executive
#37

Ed, you were always one to spot early that Germany would be a strong market. I'd say your thesis has been validated. Germany is expanding, its pipeline is expanding, and we anticipate another year of record revenues there. As for other markets abroad, we've simply made the call that at this stage we won't be investing heavily to pursue reimbursement, since that takes a couple of years. During our previous discussion with the China joint venture, they remain in the midst of running a clinical study aimed at securing NMPA clearance. Movement on that front has been fairly limited, though at present it places no real financial burden on us. Our involvement is simply maintaining routine communication with the JV's leadership team.

Ed Woo analyst
#38

Excellent. I appreciate the report. Well done on Germany. Best of luck to all of you. Thanks.

Paul Gudonis executive
#39

Thanks, Ed.

Paul Gudonis executive
#40

Operator, do we have any further questions?

Paul Gudonis executive
#41

Thanks. To briefly recap our strategy moving forward: we anticipate ongoing top-line expansion via our direct-to-patient marketing efforts, plus broadening O&P channels, as we covered regarding the Myo Connect referral program. By securing more payer agreements and working with Medicare Advantage and commercial plans on coverage, we're widening patient access to the market. As Dave outlined, we're controlling our expense structure and improving production methods to show operating leverage as we grow; we keep pursuing innovation in product development so we hold onto our leading market position. Thanks, everyone, for your questions and for your interest in Myomo; we can't wait to talk with you once more when we share our Q4 and full-year 2025 financial results roughly 4 months from now. Have a pleasant evening, all.

Operator operator
#42

Thanks a lot. That brings our call to a close. We appreciate everyone joining us for today's presentation. You're free to hang up at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Myomo, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Myomo, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.